Eton Pharma Q4 revenue up 109% to $7.3M; ET-400 NDA submission planned Q2 2024

Eton Pharmaceuticals, Inc.

Q4 2023 product sales & royalty revenue $7.3M, up 109% YoY; full-year revenue $26.1M (+132%).
Net loss of $2.3M ($0.09/share) in Q4 vs net income of $0.9M in Q4 2022; operating cash flow positive $0.4M.
ET-400 (oral hydrocortisone) passed pivotal bioequivalence study; NDA submission expected Q2 2024.
ET-600 passed pilot bioequivalence study; pivotal study planned H2 2024, NDA in early 2025.
Launched Nitisinone capsules in Feb 2024; sampling program for ALKINDI SPRINKLE went live.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Eton Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2023 results: revenue $7.3 million, net income $2.3 million, EPS $0.09 per basic and diluted share.

Period: the quarter and year ended December 31, 2023
Revenue: $7.3 million
Net income: $2.3 million
EPS: $0.09 per basic and diluted share
Result: reported results

Exact text from the filing

Net revenue: Net product sales and royalty revenues for the fourth quarter of 2023 increased by 109% to $7.3 million compared to $3.5 million in the prior year period

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-007850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.